Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.93 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | PGR | P06401 | 3/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | SHBG | P04278 | 2/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.93 |
| ▸ | MAPT | P10636 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL3098612 | 0.99 | HIF1A (0.91) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10261067 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL5699764 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13202859 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13046615 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10292969 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL15114813 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6370134 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6932400 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598506-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | Eupraxia Pharmaceuticals Inc. (CA) | 2025-08-13 | — | — | EP | claimed |
| US-20250152705-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-05-15 | — | — | US | claimed |
| CN-119968199-A | Use of long-acting fluticasone propionate injection suspension for treating and preventing gastrointestinal tract inflammation | 优普顺药物公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119095616-A | Combination therapy comprising anti-IL-23 antibodies and corticosteroids for the treatment of psoriasis | 太阳医药工业有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4463228-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | Sun Pharmaceutical Industries Limited (IN) | 2024-11-20 | — | — | EP | claimed |
| CN-117159443-B | In-situ supermolecule gel microneedle patch and preparation method and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | claimed |
| WO-2024077017-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | EUPRAXIA PHARMACEUTICALS INC. (CA) | 2024-04-11 | — | — | WO | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-117159443-A | In-situ supermolecule gel microneedle patch and preparation method and application thereof | 暨南大学 | 2023-12-05 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| EP-0752898-B1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORP (US) | 1998-04-29 | — | — | EP | claimed |
| WO-1997041144-A1 | NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS | G.D. SEARLE & CO. (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0752898-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1997-01-15 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995026782-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |